Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SVRA vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SVRA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
SVRA Overall Winner
6-Pillar Tally: SVRA 4 – 1 CAPR (1 Tie)
Matrix Metrics: SVRA 6 – 2 CAPR
As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SVRA carries a Unified Composite Score of 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SVRA vs CAPR
SVRA
Head-to-Head Winner
Savara Inc.
$4.42
-4.63% 1D
Market Cap
$1.1B
TTM Revenue
$1,000
Forward P/E
0.4x
Beta / 30D Vol
1.48β · 73% Vol
Unified Composite Score
57.7
HOLD
Tech 42.0
Fund 54.0
Flow 70.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
CAPR
Capricor Therapeutics Inc
$8.47
-11.12% 1D
Market Cap
$595.4M
TTM Revenue
$11M
Forward P/E
78.7x
Beta / 30D Vol
1.52β · 152% Vol
Unified Composite Score
28.0
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (SVRA 4 – 1 CAPR)
1. Valuation Multiples
SVRA
Forward P/E
0.4x
78.7x
Trailing P/E
0.4x
78.7x
PEG Ratio
N/M
0.38x
EV / Revenue
N/M
57.8x
2. Growth & Scale
SVRA
Revenue Growth (YoY)
+0.0%
-7.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1,000
$11M
Market Cap
$1.1B
$595.4M
3. Profitability & Quality
CAPR
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-151.0%
-100.5%
4. Balance Sheet & Cash Flow
SVRA
Cash Generation (TTM)
-$131M
-$146M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$551,000 Net Debt (0.28x D/E)
$48M Net Debt (0.44x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SVRA
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
164.3% (17th %ile)
637.1% (89th %ile)
Put/Call OI Skew
0.05x (Call-Skewed)
1.57x (Put-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Markdown
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SVRA (6) vs CAPR (2)| Institutional Metric | SVRA | CAPR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.1B | $595.4M | SVRA | |
| Trailing P/E Ratio | 0.4x | 78.7x | SVRA | |
| Forward P/E Ratio | 0.4x | 78.7x | SVRA | |
| Revenue Growth (YoY) | +0.0% | -7.9% | SVRA | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -151.0% | -100.5% | CAPR | |
| 52-Week Range Position | 13% ($4–$7) | 15% ($3–$40) | CAPR | |
| Beta / 30D Volatility | 1.48β · 73% Vol | 1.52β · 152% Vol | SVRA | |
| Unified Institutional Score | 57.7 / 100 (HOLD) | 28.0 / 100 (SELL) | SVRA | |
| Trailing 12M Revenue (USD) | $1,000 | $11M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.38x PEG · 57.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$131M ($551,000 Net Debt (0.28x D/E)) | -$146M ($48M Net Debt (0.44x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAPR +26.79 pp
3M Horizon
CAPR +37.23 pp
6M Horizon
SVRA +58.55 pp
1Y Horizon
CAPR +42.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SVRA Revenue | CAPR Revenue | SVRA Op. Margin | CAPR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -482.4% | CAPR |
| FY2018 | N/A | $0M | N/A | -917.0% | CAPR |
| FY2019 | N/A | $0M | N/A | -769.5% | CAPR |
| FY2020 | $0M | $0M | -19182.9% | -4412.6% | CAPR |
| FY2021 | N/A | $0M | N/A | -8549.9% | CAPR |
| FY2022 | N/A | $0M | N/A | -1163.9% | CAPR |
| FY2023 | N/A | $30M | N/A | -95.6% | CAPR |
| FY2024 | N/A | $20M | N/A | -191.1% | CAPR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SVRA
BREAKDOWN
Current IV
164.3%
IV Percentile
17th %ile
Put/Call OI Skew
0.05x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact SVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAPR
CONSOLIDATION
Current IV
637.1%
IV Percentile
89th %ile
Put/Call OI Skew
1.57x (Put-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SVRA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CAPR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SVRA vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SVRA carries a Unified Composite Score of 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SVRA leads the Growth & Scale pillar: SVRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), SVRA cumulative revenue shifted N/A while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, SVRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
SVRA screens cheaper on headline valuation multiples. SVRA trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRA (-151.0% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, SVRA carries 164.3% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 73% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAPR vs SVRA · Reverse Pair
SVRA vs AQST
· Sector Peer
SVRA vs SLDB
· Sector Peer
SVRA vs XERS
· Sector Peer
CAPR vs MBRX
· Sector Peer
CAPR vs AKTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem